Male Pattern Baldness Breakthrough: New Treatment Shows Promise

Breakthrough in Male Pattern Baldness Treatment: New Data Released

Beijing, China - April 21, 2026

A groundbreaking clinical trial has yielded promising results for the treatment of androgenetic alopecia (AGA) in male patients. The study, led by a team at Peking University People's Hospital, demonstrated the efficacy and safety of CG2001 foam in treating AGA.

Study Overview

A randomized, double-blind, placebo-controlled Phase II trial was conducted to evaluate the effectiveness of CG2001 foam in 110 Chinese adult men with AGA. The 30-week study aimed to identify the optimal dosing regimen for further development and assess the treatment's efficacy compared to existing therapies.

Key Findings

• The trial showed a significant improvement in hair growth, with the group receiving 5% minoxidil + 0.075% finasteride demonstrating the best results.
• Efficacy improved by approximately 50% compared to existing Chinese minoxidil foam studies.
• CG2001 foam exhibited a rapid onset of action, surpassing peak efficacy reported in comparator studies as early as Week 12.

In terms of safety, the treatment was well-tolerated and showed extremely low systemic exposure. Mild adverse reactions, such as pruritus and increased scaliness, were observed but resolved spontaneously without medical intervention.

Future Directions

The Phase II results have paved the way for further development of CG2001 foam. Dayspring Pharma will continue to advance its research and translational efforts in hair health, with a focus on bringing patients more effective and accessible treatment options.

About CG2001 Foam

CG2001 is a topical combination of minoxidil and finasteride designed to harness the synergistic potential of two cornerstone therapies for AGA. This innovative foam formulation aims to improve local follicular delivery, enhance efficacy, and minimize systemic exposure associated with oral finasteride.

About Dayspring Pharma

Dayspring Pharma is a pharmaceutical company dedicated to innovation in dermatology and hair health. The company develops differentiated therapies to address unmet clinical needs, with a focus on improving patient outcomes.

Contact: [email protected]